North America Biotechnology Market Size and Forecast 2025–2033: Innovation, Investments & the Future of Precision Science

Introduction

The biotechnology revolution is accelerating across North America, reshaping healthcare, agriculture, energy, and industrial processing. According to Renub Research, the North America Biotechnology Market is expected to reach US$ 1,592.68 billion by 2033, rising from US$ 532.72 billion in 2024, at a powerful CAGR of 12.94% during 2025–2033. This remarkable growth trajectory reflects the region’s unmatched R&D capabilities, an expanding genomic science ecosystem, rising demand for precision medicine, and aggressive government and private-sector investment into next-generation biological innovation.

Beyond its scientific depth, biotechnology is emerging as a cornerstone of economic expansion, environmental sustainability, disease management, and industrial transformation. From gene therapies and regenerative medicine to biofuels, synthetic biology, and climate-resilient agriculture, North America’s biotechnology industry is becoming a global benchmark for innovation and commercialization.

This feature explores the market's evolution, growth drivers, challenges, major regional trends, and the latest developments shaping its future through 2033.

Request Free Sample Report

North America Biotechnology Market Overview

Biotechnology integrates biological systems, living organisms, and cellular processes to develop products that improve human health, yield better crops, create sustainable materials, and protect the environment. This fusion of biology and technology supports an extraordinary range of applications:

Biopharmaceuticals & Vaccines

Genetically Modified (GM) Crops and Agri-Biotech Solutions

Industrial Biotech for Enzymes, Biofuels & Biopolymers

Environmental Biotechnology for Pollution Control

Gene Editing & Synthetic Biology

In North America, these technologies are amplified by world-class R&D infrastructure, strong funding ecosystems, leading universities, and a thriving network of biotech startups and pharmaceutical giants.

The region benefits from a robust healthcare market, rapid technological adoption, favorable government policies, and extensive private-sector collaborations. With biotech firms increasingly targeting multi-omics technologies, precision healthcare, industrial automation, and sustainable biological manufacturing, the market continues to expand into new commercial frontiers.

Key Growth Drivers of the North America Biotechnology Market

1. Expanding Cross-Sector Applications

Biotechnology in North America has moved far beyond its initial medical focus and now powers industrial, agricultural, and environmental innovation.

Healthcare & Life Sciences

Precision therapeutics

Gene and cell therapy

Diagnostic biomarkers

Regenerative medicine

mRNA vaccine pipelines

Agriculture & Food Systems

GM crops for pest resistance and climate resilience

High-yield seed technologies

Biotechnology-driven sustainable farming inputs

Industrial & Environmental Biotechnology

Biodegradable plastics

Enzyme-based industrial processes

Bioremediation and waste-to-energy solutions

Biofuel and renewable chemical production

The integration of synthetic biology, AI-based biological design, and advanced computational modeling is enabling customized biological systems. This cross-sector versatility ensures the biotechnology industry remains a central pillar of North America’s innovation economy.

2. Rising Demand for Personalized Medicine

Personalized medicine—targeted treatments designed around an individual’s genetics, behavior, and environment—is rapidly gaining adoption in the United States and Canada.

Breakthroughs in genomics and molecular diagnostics now allow clinicians to:

Identify genetic mutations

Detect disease risk earlier

Tailor drug therapies based on genetic profiles

Reduce trial-and-error prescribing in chronic diseases

The declining costs of whole-genome sequencing—from thousands of dollars to under $200—are making personalized healthcare more accessible. Biotech companies are responding with:

Targeted biologics

Gene therapies

Companion diagnostics

Precision oncology solutions

The rise of hereditary disease testing, pharmacogenomics, and chronic condition management is expected to generate billions in new biotech revenue over the forecast period.

3. Advancements in Genomic and Proteomic Technologies

North America leads the world in genomic and proteomic science, driven by:

Next-Generation Sequencing (NGS)

CRISPR-Cas9 gene editing

Multi-omics platforms combining proteomics, metabolomics, and transcriptomics

Bioinformatics and AI-enabled biomarker discovery

These breakthroughs support drug development, predictive diagnostics, and precision therapy at unprecedented speed.

A notable development occurred in July 2023, when Alexion and AstraZeneca Rare Disease partnered with Pfizer to acquire preclinical gene therapy assets, reflecting the growing demand for genomic-based therapeutics.

Enhanced protein mapping technologies are also enabling pharmaceutical companies to develop more effective biologics and monoclonal antibodies. The integration of proteomics into early-stage R&D is revolutionizing how diseases are understood at the molecular level.

Challenges Facing the North America Biotechnology Market

Despite its upward momentum, the biotechnology sector faces several systemic challenges.

1. High R&D Costs

Biotechnology innovation is incredibly capital-intensive. Bringing a new biopharmaceutical therapy to market can cost:

Over US$ 1–2 billion

Up to 10–15 years of development

Extensive regulatory requirements

Smaller biotech startups often struggle to sustain long-term R&D cycles without venture funding, partnerships, or acquisition by large pharmaceutical companies. High failure rates in clinical trials further intensify financial risk.

2. Regulatory Hurdles

The U.S. FDA, Health Canada, and other agencies enforce strict guidelines for:

Clinical trials

Biosafety

Genetic engineering

Manufacturing quality controls

Post-market surveillance

While these regulations protect public health, they can significantly delay product approvals and increase operational costs.

Additionally, regulatory differences between the U.S., Canada, and Mexico complicate cross-border commercialization. For emerging fields like gene editing and synthetic biology, evolving regulatory frameworks create further uncertainty.

United States Biotechnology Market Insights

The United States is the world’s largest and most advanced biotechnology market, powered by:

Unmatched R&D spending

Hundreds of biotech startups and unicorns

Elite research institutions (Harvard, MIT, Stanford, NIH)

Strong collaboration between academia and industry

A maturing precision medicine ecosystem

Robust venture capital investment

Biopharmaceuticals, genomic medicine, and industrial biotechnology are leading growth segments. Strategic partnerships, acquisitions, and multibillion-dollar pipeline expansions continue to shape the U.S. biotech landscape.

However, the market still faces:

Intense competition

Complex regulatory pathways

High R&D attrition rates

Despite these challenges, the United States is expected to remain a global biotechnology leader through 2033 and beyond.

Canada Biotechnology Market Insights

Canada’s biotechnology sector is expanding steadily, supported by:

Government grants

Tax incentives

A growing network of research centers

Skilled biomanufacturing talent

Key focus areas include:

Regenerative medicine

Biopharmaceutical production

Agricultural biotechnology

Sustainable industrial biotech

Genomics and proteomics

Canada is also emerging as a destination for biotech clinical trials and contract biomanufacturing. While limited funding compared to the U.S. and challenges in talent retention persist, Canada remains well-positioned for growth in precision medicine and sustainable biotech innovation.

Recent Developments Transforming the North America Biotechnology Market

North America is witnessing a wave of landmark investments, partnerships, and acquisitions:

2025 Developments

Eli Lilly acquired Verve Therapeutics for US$ 1.3 billion (June 2025) to enhance its gene-editing portfolio.

Illumina completed a US$ 425 million acquisition of SomaLogic, expanding its proteomics and multi-omic analytics capabilities.

Novartis announced a US$ 23 billion investment across five years to strengthen its U.S. biologics manufacturing and R&D footprint, including seven new facilities.

Amgen added US$ 900 million to its Ohio manufacturing expansion, taking total investment to US$ 1.4 billion.

Roche launched the Roche Genentech Innovation Center Boston, specializing in AI-driven drug discovery and CVRM diseases.

2023 Developments

Gilead Sciences partnered with Assembly Biosciences to develop innovative antiviral therapies.

Bertis Bioscience launched its Pan-omics Analysis Service in the U.S., advancing biomarker discovery and clinical research using AI and multi-omics platforms.

These activities underscore the region’s commitment to staying at the forefront of biotechnology research, production, and commercialization.

Market Segmentation

By Product Type

Instruments

Reagents

Software & Services

By Technology

Nanobiotechnology

Tissue Engineering & Regeneration

DNA Sequencing

Cell-Based Assays

Fermentation

PCR Technology

Chromatography

Others

By Application

Healthcare

Food & Agriculture

Natural Resources & Environment

Industrial Processing

Bioinformatics

Others

By Country

United States

Canada

Key Players in the North America Biotechnology Market

The region is home to world-leading biotechnology powerhouses, including:

Lonza Group AG

Amgen Inc.

Syngenta AG

Biocon Limited

Biogen Inc.

F. Hoffmann-La Roche AG

Novartis AG

Novo Nordisk A/S

Pfizer Inc.

Seagen Inc.

These companies continue to shape the competitive landscape through strong product pipelines, strategic acquisitions, and innovations in biologics, vaccines, enzyme technologies, and genomic medicine.

Final Thoughts

Biotechnology is not just a scientific discipline—it is emerging as the backbone of North America’s future economic, environmental, and healthcare systems. With the market expected to reach US$ 1.59 trillion by 2033, biotechnology is poised to influence nearly every aspect of modern life, from disease prevention to sustainable manufacturing and global food security.

Continued breakthroughs in genomics, proteomics, AI-driven drug discovery, and personalized medicine will define the next decade of growth. Meanwhile, aggressive investments by leading biotech firms and supportive government policies ensure the region remains a global biotechnology powerhouse.

As the industry evolves, North America is setting new global standards for innovation, commercialization, and scientific excellence—charting a path toward a more sustainable, healthier, and technologically advanced future.